Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation.
BACKGROUND
Angiogenin undergoes nuclear translocation and stimulates ribosomal RNA transcription in both endothelial and cancer cells. Consequently, angiogenin has a dual effect on cancer progression by inducing both angiogenesis and cancer cell proliferation. The aim of this study was to assess whether neamine, a blocker of nuclear translocation of angiogenin, possesses antitumor activity toward oral cancer.


METHODS
The antitumor effect of neamine on oral cancer cells was examined both in vitro and in vivo.


RESULTS
Neamine inhibited the proliferation of HSC-2, but not that of SAS oral cancer cells in vitro. Treatment with neamine effectively inhibited growth of HSC-2 and SAS cell xenografts in athymic mice. Neamine treatment resulted in a significant decrease in tumor angiogenesis, accompanied by a decrease in angiogenin- and proliferating cell nuclear antigen-positive cancer cells, especially of HSC-2 tumors.


CONCLUSIONS
Neamine effectively inhibits oral cancer progression through inhibition of tumor angiogenesis. Neamine also directly inhibits proliferation of certain types of oral cancer cells. Therefore, neamine has potential as a lead compound for oral cancer therapy.
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho Kita-ku, Okayama 700-8525, Japan. koujik@md.okayama-u.ac.jp.
Koji
K
Kishimoto
Shoko
S
Yoshida
Soichiro
S
Ibaragi
Norie
N
Yoshioka
Guo-Fu
GF
Hu
Akira
A
Sasaki
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology*; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D018450:Disease Progression; D005601:Framycetin / Q000494:pharmacology*; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D051379:Mice; D008819:Mice, Nude; D009062:Mouth Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000473:pathology; D021381:Protein Transport / Q000187:drug effects; D012259:Ribonuclease, Pancreatic / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D043925:Angiogenesis Inducing Agents; D005601:Framycetin; C488396:neamine; C046366:angiogenin; D012259:Ribonuclease, Pancreatic
Neamine; angiogenesis; angiogenin; cell proliferation; oral cancer